sanofi bid goes hostile , page-3

From The Motley Fool:

"The market for multiple sclerosis, or MS, treatments caters to 2.5 million patients worldwide and has become a focal point for drug developers and investors alike in recent years. sanofi-aventis (NYSE: SNY) structured its blockbuster $20 billion takeover of Genzyme (Nasdaq: GENZ) around the expected success of Genzyme's Lemtrada drug for MS. This market is a very, very big deal."

Wonder if, in the near future SA, will require the Unilife Prefill for the transport mechanism of Lemtrada?

:-)

more:
1.
Genzyme's `Theoretical Cure' for MS Draws Scrutiny, Spurs Sanofi Purchase.

"Genzyme says the drug, known as Lemtrada for MS and sold as Campath for leukemia, will reap peak annual sales of as much as $3.5 billion. While the medicine may meet that projection, indications of infections, thyroid complications and blood disorders may ultimately limit use, doctors say."

http://www.bloomberg.com/news/2011-02-16/genzyme-s-experimental-ms-drug-to-profit-investors-only-if-it-has-success.html

2.
The very high expectation Genzyme has for Campath, now known as Lemtrada.

"To get an idea of how much money is already involved in the marketing of this drug, which still has not received FDA approval"

"Genzyme has said that the drug could generate between $3 and $3.5 billion in annual sales by 2017."

http://msactivism.org/2011/01/18/the-very-high-expectation-genzyme-has-for-campath-now-known-as-lemtrada/

These two articles are a very interesting read, especially the latter.

skypiliot: Forget LOVENOX I think Lemtrada's the go for our Prefill!.